Newport News, VA, September 5, 2022– ivWatch, LLC, an IV safety company, is expanding its event presence by attending two fall nursing conferences after the pause of in-person events in 2020 and limited events in 2021. ivWatch began the 2022 calendar year with exhibits at the American Organization for Nursing Leadership Annual Conference in San Antonio, Texas and the American Association of Critical-Care Nurses’ Annual event: The National Teaching Institute & Critical Care Exposition in Houston, Texas.
The company will have its revolutionary continuous IV monitoring system that detects IV infiltrations on display at the Association for Vascular Access (AVA) conference in booth 606 from September 29 – October 3, 2022. Former AVA Board member, Russ Nassof, JD will be present in the booth to discuss the legal side of IV infiltrations. If members are not able to attend AVA in person, Russ Nassof will also be hosting a webinar later in the Fall and registration will open soon for the virtual event.
Additionally, ivWatch is exhibiting at the American Nurses Credentialling Center’s (ANCC) National Magnet Conference and the ANCC Pathway to Excellence Conference in Philadelphia, Pennsylvania on October 13-15. Booth 1149 will have IV infiltration detection technology on display, customized in-person demos will be provided, and clinicians can speak directly with globally published vascular access expert Roland Van Rens.
ivWatch technologies work as a monitoring system to notify clinicians in real-time of an IV infiltration or extravasation, which helps reduce patient harm and improve outcomes in IV therapy.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV site monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.
MEDIA CONTACT:
Erin Wendell
erin.wendell@ivwatch.com
Mobile (410) 952-3800